Vocal effects of danazol therapy. A preliminary report.
Vocal effects of danazol therapy were studied in 23 women. Before danazol therapy was started the patients were examined by a phonitrician using indirect laryngoscopy and microlaryngoscopy in stroboscopic light. A glottographic frequency indication ad modum Kitzing and a tape-recording were also made. These examinations were carried out again after 3 and 6 months of therapy. The patients mostly received 600 mg danazol daily. One of the patients noticed a very marked change in her voice after 2 weeks of therapy. This patient also had conjunctivitis and the reaction was judged to be an allergic reaction to the drug and not a hormonal side effect. In 4 of the other 22 patients the glottographic frequency indication showed a slight decrease in the mean frequency and in 3 a slight increase within the normal range of interpersonal variation. None of the patients noticed subjectively any virilization of the voice. In this preliminary study we have not found any significant vocal changes in the 23 patients tested that could be attributed to the androgenic properties of danazol.
D000293:Adolescent; D000328:Adult; D003613:Danazol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D011245:Pregnadienes / Q000494:pharmacology*; D014831:Voice / Q000187:drug effects*
D011245:Pregnadienes; D003613:Danazol